271 related articles for article (PubMed ID: 11904134)
1. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.
Umbricht D; Koller R; Vollenweider FX; Schmid L
Biol Psychiatry; 2002 Mar; 51(5):400-6. PubMed ID: 11904134
[TBL] [Abstract][Full Text] [Related]
2. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia.
Umbricht D; Vollenweider FX; Schmid L; Grübel C; Skrabo A; Huber T; Koller R
Neuropsychopharmacology; 2003 Jan; 28(1):170-81. PubMed ID: 12496954
[TBL] [Abstract][Full Text] [Related]
3. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.
Heekeren K; Daumann J; Neukirch A; Stock C; Kawohl W; Norra C; Waberski TD; Gouzoulis-Mayfrank E
Psychopharmacology (Berl); 2008 Jul; 199(1):77-88. PubMed ID: 18488201
[TBL] [Abstract][Full Text] [Related]
4. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.
Hamilton HK; D'Souza DC; Ford JM; Roach BJ; Kort NS; Ahn KH; Bhakta S; Ranganathan M; Mathalon DH
Schizophr Res; 2018 Jan; 191():87-94. PubMed ID: 28711472
[TBL] [Abstract][Full Text] [Related]
5. The effects of ketamine on the mismatch negativity (MMN) in humans - A meta-analysis.
Rosburg T; Kreitschmann-Andermahr I
Clin Neurophysiol; 2016 Feb; 127(2):1387-1394. PubMed ID: 26699665
[TBL] [Abstract][Full Text] [Related]
6. Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.
Schmidt A; Bachmann R; Kometer M; Csomor PA; Stephan KE; Seifritz E; Vollenweider FX
Neuropsychopharmacology; 2012 Mar; 37(4):865-75. PubMed ID: 22030715
[TBL] [Abstract][Full Text] [Related]
7. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.
Umbricht D; Schmid L; Koller R; Vollenweider FX; Hell D; Javitt DC
Arch Gen Psychiatry; 2000 Dec; 57(12):1139-47. PubMed ID: 11115327
[TBL] [Abstract][Full Text] [Related]
8. Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice.
Ehrlichman RS; Maxwell CR; Majumdar S; Siegel SJ
J Cogn Neurosci; 2008 Aug; 20(8):1403-14. PubMed ID: 18303985
[TBL] [Abstract][Full Text] [Related]
9. Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans.
Thiebes S; Leicht G; Curic S; Steinmann S; Polomac N; Andreou C; Eichler I; Eichler L; Zöllner C; Gallinat J; Hanganu-Opatz I; Mulert C
J Psychiatry Neurosci; 2017 Jun; 42(4):273-283. PubMed ID: 28556775
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.
Juckel G; Roser P; Nadulski T; Stadelmann AM; Gallinat J
Schizophr Res; 2007 Dec; 97(1-3):109-17. PubMed ID: 17884351
[TBL] [Abstract][Full Text] [Related]
11. The effects of glycine on auditory mismatch negativity in schizophrenia.
Greenwood LM; Leung S; Michie PT; Green A; Nathan PJ; Fitzgerald P; Johnston P; Solowij N; Kulkarni J; Croft RJ
Schizophr Res; 2018 Jan; 191():61-69. PubMed ID: 28602646
[TBL] [Abstract][Full Text] [Related]
12. Effects of NMDA receptor antagonist memantine on mismatch negativity.
Korostenskaja M; Nikulin VV; Kicić D; Nikulina AV; Kähkönen S
Brain Res Bull; 2007 May; 72(4-6):275-83. PubMed ID: 17452287
[TBL] [Abstract][Full Text] [Related]
13. NMDA Receptor Antagonist Effects on Speech-Related Mismatch Negativity and Its Underlying Oscillatory and Source Activity in Healthy Humans.
de la Salle S; Shah D; Choueiry J; Bowers H; McIntosh J; Ilivitsky V; Knott V
Front Pharmacol; 2019; 10():455. PubMed ID: 31139075
[TBL] [Abstract][Full Text] [Related]
14. Effect of ketamine on the neuromagnetic mismatch field in healthy humans.
Kreitschmann-Andermahr I; Rosburg T; Demme U; Gaser E; Nowak H; Sauer H
Brain Res Cogn Brain Res; 2001 Aug; 12(1):109-16. PubMed ID: 11489614
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.
Roser P; Haussleiter IS; Chong HJ; Maier C; Kawohl W; Norra C; Juckel G
Psychopharmacology (Berl); 2011 Dec; 218(4):611-20. PubMed ID: 21590281
[TBL] [Abstract][Full Text] [Related]
16. Changes in the duration and frequency of deviant stimuli engender different mismatch negativity patterns in temporal lobe epilepsy.
Hirose Y; Hara K; Miyajima M; Matsuda A; Maehara T; Hara M; Matsushima E; Ohta K; Matsuura M
Epilepsy Behav; 2014 Feb; 31():136-42. PubMed ID: 24412859
[TBL] [Abstract][Full Text] [Related]
17. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
Javitt DC; Zukin SR; Heresco-Levy U; Umbricht D
Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851
[TBL] [Abstract][Full Text] [Related]
18. Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers.
Bravermanová A; Viktorinová M; Tylš F; Novák T; Androvičová R; Korčák J; Horáček J; Balíková M; Griškova-Bulanova I; Danielová D; Vlček P; Mohr P; Brunovský M; Koudelka V; Páleníček T
Psychopharmacology (Berl); 2018 Feb; 235(2):491-503. PubMed ID: 29302713
[TBL] [Abstract][Full Text] [Related]
19. Glutamatergic modulation of auditory information processing in the human brain.
Gunduz-Bruce H; Reinhart RM; Roach BJ; Gueorguieva R; Oliver S; D'Souza DC; Ford JM; Krystal JH; Mathalon DH
Biol Psychiatry; 2012 Jun; 71(11):969-77. PubMed ID: 22036036
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of traxoprodil and S-ketamine on quantitative EEG and auditory event-related potentials as translational biomarkers in preclinical trials in rats and mice.
Raith H; Schuelert N; Duveau V; Roucard C; Plano A; Dorner-Ciossek C; Ferger B
Neuropharmacology; 2020 Jul; 171():108072. PubMed ID: 32243874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
